Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents
Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents
Mhaskar et al., 2016 | JAMA Oncol | Meta Analysis
Citation
Mhaskar Rahul, Djulbegovic Benjamin. Iron Supplementation for Chemotherapy-Induced Anemia in Patients Receiving Erythropoiesis-Stimulating Agents. JAMA Oncol. 2016-Nov-01;2(11):1499-1500. doi:10.1001/jamaoncol.2016.1864
Abstract
CLINICAL QUESTION: What are the benefits and harms of iron supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with ESA alone in the treatment of chemotherapy-induced anemia? BOTTOM LINE: Addition of iron to ESAs improves hematopoietic response, reduces the need for red blood cell transfusions, increases hemoglobin levels, and seems to be well tolerated. The subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the treatment of chemotherapy-induced anemia.
Key Findings
The subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the treatment of chemotherapy-induced anemia.
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | See abstract |
| Sample Size | See abstract |
| Age Range | See abstract |
| Condition | See abstract |
MeSH Terms
- Anemia
- Antineoplastic Agents
- Dietary Supplements
- Erythropoiesis
- Erythropoietin
- Hematinics
- Humans
- Induction Chemotherapy
- Iron
- Randomized Controlled Trials as Topic
Evidence Classification
- Level: Meta Analysis
- Publication Types: Comparative Study, Journal Article, Meta-Analysis
- Vertical: iron-anemia
Provenance
- PMID: 27387766
- DOI: 10.1001/jamaoncol.2016.1864
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09